Alzheimer's disease - standard of diagnosis, treatment, care, and prevention.

Alzheimer's disease (AD) is the most frequent cause of dementia in people > 60 years. This white paper summarizes the current standards of AD diagnosis, treatment, care, and prevention. Cerebrospinal fluid (CSF) and positron emission tomography (PET) measures of cerebral amyloidosis and tauopathy allow the diagnosis of AD even before dementia (prodromal stage) and provide endpoints for treatments aimed at slowing the AD course. Licensed pharmacologic symptomatic drugs enhance cholinergic pathways and moderate excess of glutamatergic transmission to stabilize cognition. Disease-modifying experimental drugs moderate or remove brain amyloidosis, but so far with modest clinical effects. Nonpharmacological interventions and a healthy lifestyle (diet, socio-affective inclusion, cognitive stimulation, physical exercise, etc.) provide some beneficial effects. Prevention mainly targets modifiable dementia risk factors such as unhealthy lifestyle, cardiovascular-metabolic and sleep-wake cycle abnormalities, and mental disorders. A major challenge for the future is telemonitoring in the real world of those modifiable risk factors.

• Publication year

  2022

• Venue

  Journal of Nuclear Medicine

• Publication date

  2022-02-10

• Fields of study

  Medicine

• Identifiers
  DOI 10.2967/jnumed.121.262239PMID 35145015PMCID PMC9258577
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Donanemab in Early Alzheimer's Disease.

  2021cited by this paper
• A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer’s disease with lecanemab, an anti-Aβ protofibril antibody

  2020cited by this paper
• World-Wide FINGERS Network: A global approach to risk reduction and prevention of dementia

  2020cited by this paper
• Discriminative Accuracy of Plasma Phospho-tau217 for Alzheimer Disease vs Other Neurodegenerative Disorders.

  2020cited by this paper
• Cerebrospinal fluid p-tau217 performs better than p-tau181 as a biomarker of Alzheimer’s disease

  2020cited by this paper
• Plasma P-tau181 in Alzheimer’s disease: relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer’s dementia

  2020cited by this paper
• Dementia prevention, intervention, and care: 2020 report of the Lancet Commission

  2020cited by this paper
• Association Between Longitudinal Plasma Neurofilament Light and Neurodegeneration in Patients With Alzheimer Disease.

  2019cited by this paper
• Meta-Analysis of Randomized Controlled Trials on the Efficacy and Safety of Donepezil, Galantamine, Rivastigmine, and Memantine for the Treatment of Alzheimer’s Disease

  2019cited by this paper
• Performance of Fully Automated Plasma Assays as Screening Tests for Alzheimer Disease–Related β-Amyloid Status

  2019cited by this paper
• AgeWell.de – study protocol of a pragmatic multi-center cluster-randomized controlled prevention trial against cognitive decline in older primary care patients

  2019cited by this paper
• High-precision plasma β-amyloid 42/40 predicts current and future brain amyloidosis

  2019cited by this paper
• What electrophysiology tells us about Alzheimer's disease: a window into the synchronization and connectivity of brain neurons.

  2019cited by this paper
• Cognitive interventions for mild cognitive impairment and dementia: An overview of systematic reviews.

  2019cited by this paper
• Use of nonintrusive sensor-based information and communication technology for real-world evidence for clinical trials in dementia

  2018cited by this paper
• Evidence-based Interpretation of Amyloid-&bgr; PET Results: A Clinician’s Tool

  2018cited by this paper
• Primary prevention of dementia: from modifiable risk factors to a public brain health agenda?

  2018cited by this paper
• Effects of a 3-Year Multi-Domain Intervention with or without Omega-3 Supplementation on Cognitive Functions in Older Subjects with Increased CAIDE Dementia Scores

  2018cited by this paper
• NIA-AA Research Framework: Toward a biological definition of Alzheimer’s disease

  2018cited by this paper
• Trends in diagnosis and treatment for people with dementia in the UK from 2005 to 2015: a longitudinal retrospective cohort study.

  2017cited by this paper
• Version 3 of the Alzheimer Disease Centers’ Neuropsychological Test Battery in the Uniform Data Set (UDS)

  2017cited by this paper
• Effectiveness of a 6-year multidomain vascular care intervention to prevent dementia (preDIVA): a cluster-randomised controlled trial.

  2016cited by this paper
• Potentially Inappropriate Medication in Community-Dwelling Primary Care Patients who were Screened Positive for Dementia

  2016cited by this paper
• Prevalence of cerebral amyloid pathology in persons without dementia: a meta-analysis.

  2015cited by this paper
• Antidementia Drug Treatment in People Screened Positive for Dementia in Primary Care

  2015cited by this paper
• Do cognitive interventions improve general cognition in dementia? A meta-analysis and meta-regression

  2015cited by this paper
• A 2 year multidomain intervention of diet, exercise, cognitive training, and vascular risk monitoring versus control to prevent cognitive decline in at-risk elderly people (FINGER): a randomised controlled trial.

  2015cited by this paper
• Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria.

  2014cited by this paper
• A critical analysis of the 'amyloid cascade hypothesis'.

  2014cited by this paper
• Toward defining the preclinical stages of Alzheimer's disease: Recommendations from the National Institute on Aging‐Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease

  2011cited by this paper
• Cerebrospinal fluid biomarkers in the differential diagnosis of Alzheimer's disease from other cortical dementias

  2010cited by this paper
• Cerebrospinal fluid protein biomarkers for Alzheimer’s disease

  2004cited by this paper
• The Repeatable Battery for the Assessment of Neuropsychological Status (RBANS): preliminary clinical validity.

  1998cited by this paper
• Alzheimer's disease: the amyloid cascade hypothesis.

  1992cited by this paper
• The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part I. Clinical and neuropsychological assesment of Alzheimer's disease

  1989cited by this paper

• IND-enabling preclinical studies of [11C]COU, a trapped metabolite PET radiotracer for monoamine oxidase-B

  2025cites this paper
• IND-Enabling Preclinical Studies of [11C]COU, a Trapped Metabolite PET Radiotracer for Monoamine Oxidase-B

  2025cites this paper
• Harnessing network pharmacology and in silico drug discovery to uncover new targets and therapeutics for Alzheimer's disease

  2025cites this paper
• Targeting Alzheimer's pathology: Tetralone- and thiochromanone-based benzyl pyridinium derivatives as promising multi-target-directed ligands.

  2025cites this paper
• Age-dependent elevation of Nr4a1 attenuates PI3K/AKT/GSK3β pathway and mediates tau hyperphosphorylation and cognitive impairments.

  2025cites this paper
• Clinical perspective on pluripotent stem cells derived cell therapies for the treatment of neurodegenerative diseases.

  2025cites this paper
• Early Alzheimer's Detection Through Voice Analysis: Harnessing Locally Deployable LLMs via ADetectoLocum, a privacy-preserving diagnostic system.

  2025cites this paper
• Global mortality, prevalence and disability-adjusted life years of Alzheimer’s disease and other dementias in adults aged 60 years or older, and the impact of the COVID-19 pandemic: a comprehensive analysis for the global burden of disease 2021

  2025cites this paper
• Ferulago angulata Extract Protects against Beta-amyloid-induced Memory Impairment Through Modulation of Monoaminoxidase Enzymes in the Rat’s Hippocampus

  2025cites this paper
• The role of neuroimaging in Alzheimer’s disease: implications for the diagnosis, monitoring disease progression, and treatment

  2025cites this paper
• Ultrasensitive and Label-Free Detection of Phosphorylated Tau-217 Protein in Alzheimer’s Disease Using Carbon Nanotube Field-Effect Transistor (CNT-FET) Biosensor

  2025cites this paper
• A multifactorial lens on risk factors promoting the progression of Alzheimer's disease.

  2024cites this paper
• Exploring Heparan Sulfate Proteoglycans as Mediators of Human Mesenchymal Stem Cell Neurogenesis

  2024cites this paper
• Co-designing Customizable Clinical Dashboards with Multidisciplinary Teams: Bridging the Gap in Chronic Disease Care

  2024cites this paper
• SLEEP DISORDERS AND RISK OF ALZHEIMER'S DISEASE: A TWO-WAY ROAD.

  2024cites this paper
• Repositioning Canagliflozin for Mitigation of Aluminium Chloride-Induced Alzheimer’s Disease: Involvement of TXNIP/NLRP3 Inflammasome Axis, Mitochondrial Dysfunction, and SIRT1/HMGB1 Signalling

  2024cites this paper
• Recent developments in translational imaging of in vivo gene therapy outcomes.

  2024cites this paper
• EEG, ERPs, and EROs in patients with cognitive deficits due to progressive neurodegenerative diseases: The dark side of the Precision Medicine.

  2023cites this paper
• Advanced extracellular vesicle bioinformatic nanomaterials: from enrichment, decoding to clinical diagnostics

  2023cites this paper
• Dapagliflozin/Hesperidin Combination Mitigates Lipopolysaccharide-Induced Alzheimer’s Disease in Rats

  2023cites this paper
• Galantamine-memantine hybrids for Alzheimer's disease: The influence of linker rigidity in biological activity and pharmacokinetic properties.

  2023cites this paper
• Cognitive Trajectories in Preclinical and Prodromal Alzheimer’s Disease Related to Amyloid Status and Brain Atrophy: A Bayesian Approach

  2023cites this paper
• Patient‐related benefits of amyloid PET imaging in dementia: Rationale and design of the German randomized coverage with evidence development study ENABLE

  2023cites this paper
• Fibroblast growth factor 10 ameliorates neurodegeneration in mouse and cellular models of Alzheimer's disease via reducing tau hyperphosphorylation and neuronal apoptosis

  2023cites this paper
• Symptomatic and Disease-Modifying Therapy Pipeline for Alzheimer’s Disease: Towards a Personalized Polypharmacology Patient-Centered Approach

  2022cites this paper
• Shared genetic architecture between the two neurodegenerative diseases: Alzheimer’s disease and glaucoma

  2022cites this paper
• The Dark Side of Alzheimer’s Disease: Neglected Physiological Biomarkers of Brain Hyperexcitability and Abnormal Consciousness Level

  2022cites this paper